Login to Your Account



Serono Signs On Graffinity As Partner For Drug Development

By Douglas Merrill


Wednesday, April 9, 2003
Graffinity AG, a specialist in preclinical drug discovery, landed a commitment from Serono SA to help fill the development pipeline of Europe's largest biotechnology company. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription